Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins

Vox Sanguinis

Volumn 84, Issue 4, 2003, Pages 300-307

  Thomas, I ^a   Di Giambattista, M ^b   Gerard C ^a   Mathys, E ^a   Hougardy, V ^b   Latour, B ^a   Branckaert, T ^b   Laub, R ^b  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b Central Department for Fractionation   (Belgium)

Author keywords

Anti NS1; Anti VP; Parvovirus B19; Polymerase chain reaction; Pooling resolution; Viral load

Indexed keywords

BETA ACTIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIBODY; VIRUS DNA; VIRUS PROTEIN;

ADULT; ARTICLE; BELGIUM; BLOOD DONOR; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOOD AND DRUG ADMINISTRATION; FRACTIONATION; GENE AMPLIFICATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARVOVIRUS; PERSISTENT INFECTION; PLASMA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEROLOGY; VALIDATION PROCESS; VIRAL CONTAMINATION; VIRUS LOAD;

ALGORITHMS; ANTIBODIES, VIRAL; BELGIUM; BLOOD DONORS; DNA, VIRAL; ERYTHEMA INFECTIOSUM; HUMANS; PARVOVIRUS B19, HUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; SEROLOGIC TESTS; VIRAL LOAD; VIRAL PROTEINS;

EID: 0038795400     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00299.x     Document Type: Article

References (36)

1. Anderson LJ: Human parvoviruses. J Infect Dis 1990; 161:603-608
2. Brown KE, Young NS: Parvovirus B19 infection and hematopoiesis. Blood Rev 1995; 9:176-182
3. Young NS, Baranski B, Kurtzman G: The immune system as mediator of virus-associated bone marrow failure: B19 parvovirus and Epstein-Barr virus. Ann N Y Acad Sci 1989; 554:75-80
4. Anderson LJ, Tsou C, Parker RA, Chorba TL, Wulff H, Tattersall P, Mortimer PP: Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986; 24:522-526
5. van Elsacker-Niele AM, Kroes AC: Human parvovirus B19: relevance in internal medicine. Neth J Med 1999; 54:221-230
6. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS: Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988; 2:1159-1162
7. Nikkari S, Roivainen A, Hannonen P, Mottonen T, Luukkainen R, Yli-Jama T, Toivanen P: Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 1995; 54:597-600
8. Lundqvist A, Tolfvenstam T, Bostic J, Soderlund M, Broliden K: Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. Scand J Infect Dis 1999; 31:11-16
9. Cassinotti P, Burtonboy G, Fopp M, Siegl G: Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997; 53:229-232
10. Anderson MJ, Lewis E, Kidd IM, Hall SM, Cohen BJ: An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (Lond) 1984; 93:85-93
11. Yee TT, Lee CA, Pasi KJ: Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet 1995; 345:794-795
12. Cohen BJ, Beard S, Knowles WA, Ellis JS, Joske D, Goldman JM, Hewitt P, Ward KN: Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 1997; 37:947-952
13. Ng PK, Dobkin MB: Pasteurization of antihemophilic factor and model virus inactivation studies. Thromb Res 1985; 39:439-447
14. Troccoli NM, McIver J, Losikoff A, Poiley J: Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 1998; 26:321-329
15. Omar A, Kempf C: Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion 2002; 42:1005-1010
16. Laub R, Stangers P: Parvovirus and blood products. Pathol Biol 2002; 50:339-348
17. Azzi A, Morfini M, Mannucci PM: The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13:194-204
18. Yee TT, Cohen BJ, Pasi KJ, Lee CA: Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93:457-459
19. Koenigbauer UF, Eastlund T, Day JW: Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000; 40:1203-1206
20. Cohen BJ, Field AM, Gudnadottir S, Beard S, Barbara JA: Blood donor screening for parvovirus B19. J Virol Methods 1990; 30:233-238
21. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P: Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993; 31:323-328
22. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Matsunaga Y, Chiba S: Large-scale screening for human parvovirus B19 DNA in clinical specimens by dot blot hybridization and polymerase chain reaction. J Med Virol 1995; 47:438-441
23. Brown KE, Young NS, Alving BM, Barbosa LH: Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41:130-135
24. von Poblotzki A, Hemauer A, Gigler A, Puchhammer-Stockl E, Heinz FX, Pont J, Laczika K, Wolf H, Modrow S: Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis 1995; 172:1356-1359
25. Jones LP, Erdman DD, Anderson LJ: Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. J Infect Dis 1999; 180:500-504
26. Finkel TH, Torok TJ, Ferguson PJ, Durigon EL, Zaki SR, Leung DY, Harbeck RJ, Gelfand EW, Saulsbury FT, Hollister JR, Anderson LJ: Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994; 343:1255-1258
27. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T: Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985; 82:6133-6137
28. European Department for the Quality of Medicines: Guidelines for Validation of Nucleic Acid Amplification Technology (NAT) for the Detection of Hepatitis C Virus (HCV) RNA in Plasma Pools. Biological Substances 1999 [PA/PH/OMCL (98)22,DEF]. Strasbourg, European Department for the Quality of Medicine, 1999
29. Saldanha J, Lelie N, Yu MW, Heath A: Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002; 82:24-31
30. Parker JM, Guo D, Hodges RS: New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 1986; 25:5425-5432
31. Parker JM, Hodges RS: Prediction of surface and interior regions in proteins - Part II. Predicting secondary structure in regions bound by surface-exposed regions. Pept Res 1991; 4:355-363
32. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR: Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986; 58:921-936
33. Ferguson M, Walker D, Cohen B: Report of a collaborative study to establish the international standard for parvovirus B19 serum IgG. Biologicals 1997; 25:283-288
34. Schmidt I, Blümel J, Willkommen H, Löwer J: Parvovirus B19 in plasma pools and plasma derivatives. Vox Sang 2001; 81:228-235
35. Jordan J, Tiangco B, Kiss J, Koch W: Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998; 75:97-102
36. Weimer T, Streichert S, Watson C, Groner A: High-titer screening PCR, a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001; 41:1500-1504